SCODiA Report by MLBI Lab

Single-Cell Analysis Reveals Subtype-Specific Heterogeneity and Therapeutic Vulnerabilities in Breast Cancer

This comprehensive single-cell analysis of breast tissue identifies distinct cellular landscapes and molecular signatures across different breast cancer subtypes (ER+, HER2+, TNBC) compared to normal tissue. We delineate tumor-origin epithelial cells by widespread aneuploidy and characterize subtype-specific alterations in cell population composition, genomic instability, and cell-cell communication networks. The findings highlight profound metabolic reprogramming, altered immune microenvironments with T cell exhaustion and macrophage polarization, and dysregulated cell cycle progression, collectively driving tumor progression and offering a diverse array of potential therapeutic targets.

Contents

  1. Dataset overview
  2. UMAP Visualization of Cell-level Annotations across Conditions, Samples, Cell Types, and Ploidy States
  3. Major Cell Type Score and Ploidy Distribution on UMAP
  4. Marker Expression Dot Plot for Cell Type Subsets
  5. Copy Number Variation Analysis of Tumor-Origin Epithelial Cells in Breast Cancer
  6. CNV-aware UMAP Visualization of Cell Type, Ploidy, Condition, and Sample
  7. Minor Cell Type Population Analysis Across Breast Cancer Subtypes and Normal Tissue
  8. T Cell and Innate Lymphoid Cell Subpopulation Analysis in Breast Cancer Subtypes
  9. T cell Subset Population Differences Across Breast Cancer Conditions
  10. Cell Population Composition Across Breast Cancer Subtypes and Normal Tissue
  11. Macrophage Subset Population Differences Across Breast Cancer Conditions
  12. Ploidy Status of Tumor-Origin Epithelial Cells Across Breast Cancer Subtypes
  13. Cell-Cell Interaction Patterns Across Breast Cancer Subtypes and Normal Tissue
  14. Condition-Specific Cell-Cell Interaction Patterns in Breast Cancer Subtypes
  15. Condition-Specific Cell-Cell Interaction Patterns Involving Immune Checkpoint and Cell Cycle Pathways in Breast Cancer
  16. Epithelial Cell Condition-Specific Surfaceome Markers in Breast Cancer
  17. Macrophage Condition-Specific Surfaceome Marker Analysis in Breast Cancer Subtypes
  18. Fibroblast Condition-Specific Surfaceome Markers in Breast Cancer
  19. T cell CD4+ Surfaceome Marker Expression in Breast Cancer Subtypes
  20. Differential Expression of Cell Cycle Pathway Genes in Breast Epithelial Cells Across Cancer Subtypes
  21. Gene Ontology (GSA) Analysis of Epithelial Cells in Breast Cancer Subtypes
  22. Gene Set Enrichment Analysis (GSEA) Across Breast Cancer Subtypes and Cell Types
  23. Discussion
  24. Query List

0. Dataset overview

Dataset Summary

Inferred Disease/Biological Context

1. UMAP Visualization of Cell-level Annotations across Conditions, Samples, Cell Types, and Ploidy States

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a series of UMAP visualizations designed to explore the relationships between different cell-level annotations in the single-cell RNA-seq dataset. The UMAP plots display the distribution of cells colored by condition, sample, celltype_major, celltype_minor, ploidy_dec, and celltype_subset. This helps to assess the overall dataset structure, evaluate annotation quality, identify potential batch effects, and observe the spatial relationships of key biological features in a reduced-dimension space.

Visual Summary

Condition UMAP

The UMAP plot colored by condition shows a clear separation between 'Normal' cells (light green) and cells from cancer subtypes (ER+, HER2+, TNBC). 'Normal' cells primarily occupy distinct clusters, particularly on the right side of the embedding. The cancer subtypes (ER+, HER2+, TNBC) largely overlap and intermingle in other regions of the UMAP, though some sub-clusters appear to be enriched for specific cancer types (e.g., TNBC cells (dark blue) show a noticeable presence in the lower-left dense cluster and some smaller peripheral clusters, while ER+ cells (dark red) are more widely distributed across the tumor-associated regions). This suggests a common transcriptional landscape for many cells within the tumor microenvironment, but also some subtype-specific features.

Sample UMAP

The sample UMAP reveals that cells from individual samples (represented by distinct colors) are generally well-interspersed across the embedding, particularly within the 'Normal' region and also within the tumor-associated regions. While some localized areas show enrichment for specific samples, there are no large, distinct clusters composed predominantly of cells from a single sample. This indicates a good integration of samples, minimizing severe batch effects that could obscure biological signals.

Cell Type (Major, Minor, and Subset) UMAPs

The celltype_major, celltype_minor, and celltype_subset UMAPs demonstrate robust clustering of distinct cell populations.

Ploidy_dec UMAP

The ploidy_dec UMAP shows a striking pattern: 'Aneuploid' cells (dark red) predominantly occupy the dense clusters associated with the tumor conditions (ER+, HER2+, TNBC) in the lower and central parts of the UMAP. 'Diploid' cells (light yellow) are widely distributed but are the predominant population in the clusters associated with 'Normal' conditions and also comprise a significant portion of the tumor-associated stromal and immune cells. 'Unclear' cells (dark blue) are very few and scattered. This visual separation strongly supports the biological distinction between normal and cancerous cell populations based on ploidy status, with aneuploidy being a key characteristic of the tumor compartment.

Biological Interpretation

The UMAP visualizations provide crucial insights into the cellular landscape of breast cancer, integrating genomic and transcriptional features.

  1. Tumor Microenvironment Heterogeneity: The intermingling of ER+, HER2+, and TNBC cells in certain regions of the UMAP, juxtaposed with distinct normal cell clusters, highlights the complex and heterogeneous nature of the tumor microenvironment. While specific cancer subtypes share commonalities, their unique characteristics likely contribute to the subtle differences observed in their distribution. The presence of both normal and tumor-associated cells across various regions underscores the intricate cellular interactions within the breast tissue.
  2. Aneuploidy as a Tumor Hallmark: The clear segregation of 'Aneuploid' cells to tumor-associated regions and 'Diploid' cells to normal regions, as well as some tumor-associated non-malignant cells, strongly corroborates aneuploidy as a defining characteristic of cancer cells. Given that Epithelial cells are the "Resolved tumor-origin cell type," it is highly likely that the 'Aneuploid' population within the epithelial clusters represents the malignant cancer cells. This reinforces the biological distinction between malignant and non-malignant cells at a single-cell level.
  3. Cell Type Annotation Quality: The distinct and well-separated clusters for celltype_major, celltype_minor, and celltype_subset indicate high confidence in the cell type annotations. The hierarchical nature of the annotations, from broad major types to highly specific subsets, is well-resolved in the UMAP space. This robust annotation is critical for downstream analyses, ensuring that differential expression, pathway analyses, and cell-cell interaction studies are performed on accurately defined cell populations.
  4. Integrated View of Tumor Biology: The combined view of condition, cell type, and ploidy highlights how the disease state (cancer subtype) is deeply intertwined with changes in cell type composition and genomic stability. For instance, the epithelial clusters that largely overlap with aneuploid cells and cancer conditions likely represent the transformed malignant epithelial cells, while the diploid epithelial cells in normal regions represent healthy mammary epithelium. Similarly, the immune and stromal cells within tumor-associated regions, despite often being diploid, contribute to the unique microenvironment of different cancer subtypes.

Annotation Notes

2. Major Cell Type Score and Ploidy Distribution on UMAP

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a series of UMAP (Uniform Manifold Approximation and Projection) plots, which are dimensionality reduction visualizations, to illustrate the distribution of different major cell types and ploidy status across the single-cell RNA-sequencing dataset. Each plot displays the UMAP embedding of all cells, with individual plots highlighting the calculated score for a specific major cell type, or the assigned ploidy status, alongside a reference UMAP colored by the dataset's celltype_major annotation. This allows for an assessment of the distinctiveness of cell populations and the spatial relationship between cell identities and ploidy in the breast tissue context.

Visual Summary

The UMAP projections reveal a complex landscape of cellular heterogeneity, with distinct clusters representing different cell populations.

Biological Interpretation

The UMAP visualizations provide crucial insights into cell type composition and the distribution of ploidy within the breast tissue.

  1. Robust Cell Type Identification: The strong concordance between the high cell type scores and the celltype_major annotations indicates that the cell type identification method used (likely HiCAT given the plot titles) is robust and accurately delineates distinct cell populations in the dataset. Each major cell type forms a coherent and largely non-overlapping cluster, suggesting clear transcriptional profiles for these populations.
  2. Tumor Cell Localization and Identity: The data context specifies 'Epithelial cell' as the 'Resolved tumor-origin cell type' for breast cancer. The UMAP plots strongly support this:
  1. Immune and Stromal Compartment: The immune cells (T cells, B cells, Plasma cells, Myeloid cells, Mast cells) and stromal components (Fibroblasts, Smooth muscle cells, Endothelial cells - likely inferred from "Stromal cell" and "Endothelial cell" scores) are predominantly diploid and form distinct clusters separate from the aneuploid epithelial cell mass. This is expected, as these are typically non-malignant cells forming the tumor microenvironment (TME) or normal tissue components. Their distinct clustering and diploid status confirm their identity as supporting cells rather than cancerous cells.
  2. Breast Cancer Context: Given the "Breast" tissue and conditions like "TNBC, HER2+, ER+", the identification of aneuploid epithelial cells is highly consistent with the presence of breast carcinoma. The clear separation of tumor (aneuploid epithelial) from non-tumor (diploid stromal and immune) populations on the UMAP is critical for subsequent analyses like differential gene expression or cell-cell interaction studies, ensuring comparisons are made within appropriate cellular contexts.

Annotation Notes

The UMAP plots demonstrate high-quality cell type annotation, with distinct clusters for each major cell type and clear spatial separation. The HiCAT_major_score values align well with the celltype_major labels, confirming the reliability of the cell type assignments. The ploidy_dec annotation effectively segregates aneuploid (tumor-associated) cells within the epithelial compartment from the diploid non-tumor cells, which is a critical feature for understanding the tumor microenvironment in breast cancer. The embedding structure is well-resolved, allowing for clear visual interpretation of cellular identities and characteristics.

3. Marker Expression Dot Plot for Cell Type Subsets

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a marker expression dot plot to visualize the specific gene expression patterns across various celltype_subset populations identified in the single-cell RNA-seq dataset. The primary objective is to evaluate the robustness and specificity of the assigned cell type annotations by examining the expression of known and algorithmically identified marker genes. Each dot represents a gene-cell type pair, with dot size indicating the fraction of cells within that group expressing the gene, and color intensity representing the mean expression level of the gene within that group. Genes are grouped along the x-axis, and cell type subsets are displayed on the y-axis, with cell counts per group shown on the right.

Visual Summary

The dot plot effectively displays the expression profiles of numerous marker genes across 40 distinct celltype_subset populations. Key observations include:

Biological Interpretation

The marker expression dot plot provides strong evidence for the distinct identities of the celltype_subset populations.

Annotation Notes

The comprehensive and specific marker gene expression patterns observed across the celltype_subset populations strongly support the current cell type annotations. The distinct profiles for immune cell subsets, epithelial cells, and stromal components indicate a robust cell type identification process. There are no major anomalies or unexpected overlaps that would suggest significant misannotation. The identified markers align well with known biological functions and cell identities. This robust annotation is foundational for subsequent analyses, particularly when investigating condition-specific changes in cell populations or gene expression in the context of breast cancer.

4. Copy Number Variation Analysis of Tumor-Origin Epithelial Cells in Breast Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis characterizes copy number variations (CNVs) within tumor-origin epithelial cells from single-cell RNA-seq data of breast tissue. The primary goal is to visualize CNV patterns across different samples and conditions, identify regions of significant amplification, and correlate these findings with established breast cancer subtypes. The plot_cnv_heatmap tool was applied to specifically target 'Epithelial cell' populations, grouped by sample, with a summary highlighting frequently amplified genomic regions.

Visual Summary

CNV Heatmap (log2(CNR))

The top panel displays a heatmap of log2(Copy Number Ratio, CNR) across genomic spots for individual cell groups, which are identified by sample and ploidy status, or by sample and condition for aneuploid cells.

Copy Number Amplification (CNA) Summary

The bottom panel provides a concise summary of regions with significantly amplified copy numbers.

Biological Interpretation

The CNV analysis of epithelial cells effectively distinguishes between presumably normal/diploid cells and tumor-associated aneuploid cells across different breast cancer subtypes. The presence of significant and heterogeneous CNVs in ER+, HER2+, and TNBC epithelial cells strongly supports their cancerous origin and genomic instability.

Clinical or Translational Implications

The identification of specific CNV patterns in tumor-origin epithelial cells has significant clinical and translational implications:

5. CNV-aware UMAP Visualization of Cell Type, Ploidy, Condition, and Sample

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents five UMAP (Uniform Manifold Approximation and Projection) plots, where the embedding was generated considering CNV (Copy Number Variation) patterns. Each plot visualizes the same underlying cellular landscape but is colored according to different metadata attributes: major cell type, minor cell type, ploidy status, disease condition, and individual sample. The primary goal is to understand how these biological and technical variables are distributed within the CNV-driven embedding, providing insights into cell identity, tumor-normal separation, and heterogeneity.

Visual Summary

Biological Interpretation

The UMAPs generated using CNV patterns effectively delineate biologically meaningful cell populations.

  1. Tumor-Normal Segregation: The most significant finding is the clear separation of Aneuploid cells from Diploid cells. This indicates that the CNV-aware embedding successfully captures a fundamental genomic characteristic of cancer cells. The Diploid population largely corresponds to Normal condition samples and various stromal and immune cell types, which are expected to maintain diploidy.
  2. Tumor Cell Identity: The Aneuploid cells are predominantly found within the Epithelial cell major and minor clusters. This aligns perfectly with the data context indicating 'Epithelial cell' as the 'Resolved tumor-origin cell type' for breast cancer (a carcinoma). This provides strong evidence for the accurate identification of malignant epithelial cells.
  3. Disease Subtype Distribution: The cancer conditions (ER+, HER2+, TNBC) largely localize to the aneuploid, epithelial regions of the UMAP. While some distinct clusters can be observed for specific subtypes, the substantial overlap suggests common genomic or transcriptomic features driving the overall tumor structure. The distinct peripheral clusters within the aneuploid region might represent specific subclones or unique genomic alterations driving divergence between subtypes or within a subtype.
  4. Cell Type Specificity: The distinct clustering of major and minor cell types, even within a CNV-driven embedding, demonstrates that the UMAP effectively preserves cellular identity while highlighting CNV-related differences. Non-epithelial cells (Stromal, T cells, Myeloid, Endothelial) generally maintain their unique spatial relationships, suggesting their distinct biological functions and origins are conserved.
  5. Inter-patient Heterogeneity: The sample plot underscores the significant heterogeneity among individual patients, even within the same breast cancer subtype. Different samples exhibit unique spatial patterns within the aneuploid landscape, which may reflect varying genomic alterations, tumor microenvironment compositions, or disease progression states. This inter-patient variability is a critical aspect of cancer biology and clinical management.

Annotation Notes

These UMAP visualizations serve as a robust validation of the cell type annotations, ploidy assignments, and the underlying data structure. The clear stratification by ploidy, which aligns with disease status and cell type, confirms the quality and reliability of these annotations. The CNV-aware embedding successfully captures the distinct molecular profiles that define both normal and malignant cell populations, as well as the inherent complexity and heterogeneity within breast cancer samples. This visual evidence supports the use of these annotations for downstream, more focused analyses.

6. Minor Cell Type Population Analysis Across Breast Cancer Subtypes and Normal Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative abundance of minor cell types within individual samples, grouped by distinct breast cancer conditions (ER+, HER2+, TNBC) and Normal tissue. Each bar represents a single sample, with stacked segments showing the percentage contribution of different celltype_minor populations. This visualization provides insights into the cellular composition and heterogeneity of the tumor microenvironment (TME) and normal breast tissue.

Visual Summary

The stacked bar plots display the proportional distribution of 14 minor cell types across a total of 39 samples, categorized under four conditions: ER+ (18 samples), HER2+ (5 samples), Normal (10 samples), and TNBC (6 samples).

Biological Interpretation

The observed cell type population distributions reflect distinct microenvironmental characteristics across different breast cancer subtypes and normal tissue, underscoring the heterogeneity of breast cancer.

Immune Microenvironment Heterogeneity

Clinical or Translational Implications

The differential cellular composition across breast cancer subtypes has significant clinical and translational implications:

7. T Cell and Innate Lymphoid Cell Subpopulation Analysis in Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of various T cell subsets, NK cells, and Innate Lymphoid Cells (ILCs) within samples from Normal breast tissue and different breast cancer subtypes (ER+, HER2+, TNBC). Each bar represents an individual sample, with stacked segments showing the percentage contribution of each lymphoid cell subset. This visualization allows for a comparative assessment of the immune cell landscape across different disease states and subtypes.

Visual Summary

The stacked bar plots reveal distinct patterns in the composition of lymphoid cell populations:

Biological Interpretation

The observed shifts in lymphoid cell populations provide critical insights into the immune microenvironment of breast cancer:

  1. Dysregulation of Innate Immunity in Cancer: The substantial reduction of ILCs (ILC1, ILC2, ILC3, ILCreg) and NK cells in breast cancer samples compared to normal tissue suggests a compromised innate immune surveillance and anti-tumor response. ILC1s and NK cells are crucial for early tumor recognition and elimination via cytokine production (e.g., IFN-γ) and direct cytotoxicity, respectively. Their diminished presence could facilitate tumor escape.
  2. Adaptive Immune Response with Exhaustion and Suppression:
  1. Subtype-Specific Immunophenotypes: While there are common themes, the precise balance of effector, exhausted, and regulatory T cells varies across ER+, HER2+, and TNBC subtypes and individual samples, indicating potentially distinct immune evasion strategies or inflammatory milieus. For example, TNBC, often considered more immunogenic, shows a significant proportion of exhausted T cells, suggesting an ongoing but ultimately ineffective immune battle.

Clinical or Translational Implications

The findings have several potential clinical and translational implications:

  1. Prognostic Biomarkers: The relative proportions of specific lymphoid subsets, particularly the ratio of effector T cells to exhausted T cells or Tregs, could serve as prognostic markers for different breast cancer subtypes. A higher proportion of exhausted or regulatory T cells might correlate with poorer patient outcomes.
  2. Immunotherapy Strategies:
  1. Subtype-Specific Treatment Approaches: The observed differences in immune composition across ER+, HER2+, and TNBC suggest that immunotherapy approaches might need to be tailored to the specific breast cancer subtype and individual patient's immune profile. For example, TNBC, with its higher immunogenicity and T cell exhaustion, may be more responsive to certain immunotherapies compared to other subtypes.

8. T cell Subset Population Differences Across Breast Cancer Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportions of T cell subsets, specifically Cytotoxic T cells (T_Cyto) and Regulatory T cells (Treg), across different breast cancer conditions (ER+, Normal, HER2+, TNBC) relative to their total T cell populations. The aim is to identify statistically significant differences in these immune cell populations that may contribute to distinct tumor microenvironments characteristic of each breast cancer subtype. The box plots display the distribution of celltype proportions for each condition, with individual data points overlaid as stripplots, and p-values indicating statistical significance of pairwise comparisons (with a cutoff of p < 0.1).

Visual Summary

The analysis reveals significant differences in the proportions of both Cytotoxic T cells (T_Cyto) and Regulatory T cells (Treg) across breast cancer subtypes compared to normal tissue, and also between certain subtypes.

Cytotoxic T cells (T_Cyto):

Regulatory T cells (Treg):

Biological Interpretation

These findings highlight distinct immunological landscapes within different breast cancer subtypes.

Clinical or Translational Implications

The observed differences in T cell subset populations have several clinical and translational implications for breast cancer management:

9. Cell Population Composition Across Breast Cancer Subtypes and Normal Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of various cell subsets within individual samples, grouped by different breast cancer conditions (ER+, HER2+, TNBC) and Normal breast tissue. While the user query specifically asked for macrophage subsets, the generated plot displays the comprehensive cell type composition at the celltype_subset granularity, allowing for a broader understanding of the tumor microenvironment. Each bar represents a single sample, and the colored segments indicate the percentage contribution of each identified cell type subset.

Visual Summary

The stacked bar plots reveal distinct patterns in cell type composition across the different conditions:

Biological Interpretation

The observed shifts in cell population compositions provide valuable insights into the biology of breast cancer subtypes:

Macrophage Infiltration and Polarization:

Clinical or Translational Implications

The distinct cellular compositions observed across breast cancer subtypes have several clinical and translational implications:

10. Macrophage Subset Population Differences Across Breast Cancer Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents box plots illustrating the proportions of three distinct macrophage subsets – Macrophage (M1), Macrophage (M2B), and Macrophage (M2C) – across different breast cancer conditions (ER+, TNBC, HER2+) and Normal breast tissue. Statistical significance was assessed using a p-value cutoff of 0.1. The aim is to identify and interpret changes in macrophage polarization within the tumor microenvironment of various breast cancer subtypes.

Visual Summary

The box plots reveal subtype-specific shifts in macrophage proportions:

Macrophage (M1)

Macrophage (M2B)

Macrophage (M2C)

Biological Interpretation

Macrophages are highly plastic immune cells that play diverse roles in cancer, often polarizing into pro-inflammatory (M1-like) or pro-tumorigenic (M2-like) phenotypes within the tumor microenvironment (TME). The observed shifts in macrophage subsets provide insights into the immune landscape of breast cancer:

Divergent M2C Macrophage Dynamics in TNBC vs. HER2+:

These findings collectively suggest a complex and dynamic macrophage landscape in breast cancer, with distinct polarization patterns emerging across different molecular subtypes. The balance and functional state of these macrophage subsets are crucial determinants of tumor progression and response to therapy.

Clinical or Translational Implications

11. Ploidy Status of Tumor-Origin Epithelial Cells Across Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the ploidy status (Aneuploid, Diploid, or Unclear) of tumor-origin cells, specifically identified as Epithelial cells, across different breast cancer conditions: ER+, HER2+, Normal, and TNBC. The goal is to visualize the proportions of these ploidy states within individual samples for each condition, providing insight into the genomic stability characteristics of tumor cells in different breast cancer subtypes.

Visual Summary

The bar plots display the relative proportions of aneuploid, diploid, and unclear cells within the epithelial compartment for each sample, grouped by condition.

Biological Interpretation

The observed ploidy patterns strongly corroborate the malignant nature of the identified tumor-origin epithelial cells and highlight differences across breast cancer subtypes.

  1. Aneuploidy as a Cancer Hallmark: The stark contrast between the uniformly diploid state of epithelial cells in 'Normal' samples and the significant presence of aneuploid epithelial cells in ER+, HER2+, and TNBC conditions is a classic characteristic of cancer. Aneuploidy, defined as an abnormal number of chromosomes, is a fundamental hallmark of cancer, driving genomic instability and contributing to tumor evolution and heterogeneity. This observation confirms the effectiveness of the ploidy calling method in distinguishing malignant from benign epithelial cells [1].
  2. Confirmation of Tumor-Origin Cell Type: The analysis focuses on epithelial cells, which are the origin of breast carcinomas. The detection of aneuploidy almost exclusively within these cells in cancer conditions, and its absence in normal epithelial cells, strongly supports their identification as the primary tumor cell population within the samples.
  3. Subtype-Specific Genomic Instability:

Clinical or Translational Implications

This analysis provides foundational insights with several potential clinical and translational implications:

---

References:

[1] Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation. *Cell, 144*(5), 646-674. PubMed Search: "Hallmarks of Cancer" site:pubmed.ncbi.nlm.nih.gov

[2] Gordon, D. J., & Resnick, A. C. (2018). The Role of Aneuploidy in Cancer. *Annual Review of Genomics and Human Genetics, 19*, 23-45. PubMed Search: "Aneuploidy cancer prognosis" site:pubmed.ncbi.nlm.nih.gov

12. Cell-Cell Interaction Patterns Across Breast Cancer Subtypes and Normal Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns using CellPhoneDB, focusing on key cell types relevant to the breast tumor microenvironment: Epithelial cells (both diploid and aneuploid), Fibroblasts, Macrophages, and T cells (CD4+ and CD8+). The interactions are compared across different breast cancer subtypes (ER+, HER2+, TNBC) and normal breast tissue to identify condition-specific communication networks. The dot plots visualize the significance (-log10(p)) and strength (log2(mean)) of ligand-receptor interactions, providing insights into the molecular dialogues that shape disease progression and tissue homeostasis.

Visual Summary

The provided dot plots illustrate distinct cell-cell interaction landscapes for Normal breast tissue, ER+ breast cancer, HER2+ breast cancer, and Triple-Negative Breast Cancer (TNBC).

Key visual observations for each condition:

Biological Interpretation

Normal Breast Tissue Interactions

In normal breast tissue, the predominant interactions highlight processes essential for tissue architecture and homeostasis. The extensive involvement of integrin complexes (e.g., COL1A1-integrin_a1b1, LAMA3-integrin_a3b1) in Fibroblast-Fibroblast and Diploid Epithelial cell-Diploid Epithelial cell interactions underscores the critical role of cell-ECM adhesion and cell-cell contact in maintaining tissue integrity and structure. The active TGFB2 and WNT2 signaling pathways are crucial for regulating epithelial cell proliferation, differentiation, and overall tissue development and repair processes. The presence of HGF-MET and IGF1-IGF1R signaling suggests a baseline level of growth factor activity supporting tissue maintenance.

ER+ Breast Cancer Interactions

In ER+ breast cancer, there's a clear shift towards interactions involving aneuploid epithelial cells and macrophages. The high activity of APOE-TREM2_receptor, APP-CD74, and CLU-TREM2_receptor interactions suggests active communication pathways between macrophages and epithelial cells. TREM2 (Triggering Receptor Expressed on Myeloid cells) is often associated with macrophage activation and efferocytosis (clearance of apoptotic cells) in the tumor microenvironment, potentially supporting tumor cell survival or modulating immune responses PubMed Search: TREM2 breast cancer. The strong VEGFA-NRP2 axis between macrophages and aneuploid epithelial cells is highly relevant, as VEGFA is a potent pro-angiogenic factor, promoting tumor vascularization and growth GeneCards: VEGFA. The homotypic MPZL1-MPZL1 interaction among aneuploid epithelial cells might play a role in tumor cell adhesion or survival.

HER2+ Breast Cancer Interactions

HER2+ breast cancer displays a highly inflamed and immune-active microenvironment. The significant presence of various chemokine-CCR1 axes (CCL3/3L1/4/5-CCR1) engaging macrophages and T cells points towards robust immune cell recruitment and activation, consistent with the immune-infiltrated nature often seen in HER2+ tumors. Crucially, the HB-EGF_ERBB2 interaction in Macrophage-Macrophage (and other) pairs is highly relevant, as HB-EGF is a known ligand for HER2 (ERBB2), suggesting potential autocrine or paracrine activation of HER2 signaling within the tumor microenvironment, which can drive proliferation and resistance GeneCards: HB-EGF. The presence of ProstaglandinE2-PTGER interactions involving T cells and macrophages indicates potential immunosuppressive mechanisms, as PGE2 can modulate immune cell function. LGALS9-P4HB and TGFB1-integrin_avb6 interactions further highlight mechanisms of immune modulation and potential ECM remodeling, both of which are critical in tumor progression and immune escape.

TNBC Breast Cancer Interactions

TNBC exhibits the most complex and robust interaction network, reflecting its aggressive nature and highly desmoplastic and immunosuppressive microenvironment. The widespread and strong activity of SPP1-integrin (e.g., SPP1-integrin_a4b1, aVb1, aVb5) interactions involving fibroblasts, macrophages, and aneuploid epithelial cells is a hallmark. Secreted Phosphoprotein 1 (SPP1, also known as Osteopontin) is a major pleiotropic cytokine implicated in inflammation, angiogenesis, metastasis, and immune suppression in TNBC PubMed Search: SPP1 TNBC. The extensive integrin complexes activity, even more pronounced than in normal tissue, suggests significant ECM remodeling and altered cell-matrix interactions that promote invasion and metastasis. WNT2 signaling is broadly active, indicating its potential role in regulating cancer stemness, proliferation, and immune evasion PubMed Search: WNT2 breast cancer. PLAU-PLAUR (Plasminogen Activator, Urokinase - Urokinase Plasminogen Activator Receptor) interactions signify increased proteolytic activity, critical for tumor invasion and metastasis GeneCards: PLAU. The strong LGALS9-P4HB, TGFB1-integrin, and VEGFA-NRP1/2 interactions point towards potent immunosuppressive mechanisms, extensive ECM remodeling, and angiogenesis, respectively, all contributing to TNBC's aggressive phenotype.

Role of Aneuploid Epithelial Cells

Aneuploid epithelial cells, representing the tumor cells, are central players in the interactions across all cancer subtypes. Their diverse and strong interactions with stromal (fibroblasts), immune (macrophages, T cells), and other epithelial cells underscore their active role in reshaping the tumor microenvironment. The presence of specific pro-tumorigenic interactions (e.g., VEGFA, SPP1, HB-EGF) with these aneuploid cells highlights their capacity to recruit immune cells, induce angiogenesis, and facilitate invasion, thus driving tumor progression.

Clinical or Translational Implications

The distinct cell-cell interaction patterns identified offer several potential clinical and translational implications:

  1. Therapeutic Target Prioritization:
  1. Biomarker Discovery: Specific highly significant and strong ligand-receptor pairs, unique to each subtype, could serve as diagnostic or prognostic biomarkers. For instance, high activity of SPP1-integrin or WNT2 interactions might indicate a more aggressive TNBC phenotype.
  2. Experimental Validation: The identified high-confidence CCI pairs warrant further experimental validation. This could involve:
  1. Combination Therapies: Understanding the specific communication pathways can inform rational design of combination therapies. For example, in TNBC, combining agents that target SPP1-integrin interactions with WNT pathway inhibitors or immune checkpoint blockades could lead to synergistic effects. In HER2+ disease, anti-HER2 therapies could be combined with agents targeting HB-EGF or chemokine axes to enhance efficacy.

13. Condition-Specific Cell-Cell Interaction Patterns in Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates condition-specific cell-cell interaction (CCI) patterns involving Epithelial cells, major immune cells (T cell, B cell, Plasma cell, Mast cell, Myeloid cell), and stromal cells (Fibroblast, Endothelial cell, Smooth muscle cell) across different breast cancer subtypes (ER+, HER2+, TNBC) and normal breast tissue. The dot plot visualizes the strength and significance of these interactions, allowing for the identification of differentially regulated intercellular communications in the tumor microenvironment (TME) of various breast cancer conditions compared to normal tissue. The max_n_items_per_group parameter was set to 60, displaying up to 60 most significant interactions for each condition.

Visual Summary

The dot plot reveals distinct and extensive cell-cell interaction landscapes across the different conditions. The size of the dot corresponds to the significance (-log10(p-value)), and the color intensity reflects the scaled log strength of the interaction.

Biological Interpretation

The observed differential CCI patterns underscore the dynamic interplay between tumor cells and their microenvironment in breast cancer progression, with distinct features for each subtype.

1. Altered Extracellular Matrix (ECM) Remodeling and Cell Adhesion

Prominent CCIs in Cancer (e.g., TNBC, ER+, HER2+):

Prominent CCIs in Normal (e.g., in N-MH0023-Total):

2. Immune Cell Recruitment and Modulation in the TME

Prominent CCIs in Cancer (especially TNBC):

3. Growth Factor and Angiogenic Signaling

Prominent CCIs in Cancer (e.g., ER+, HER2+, TNBC):

Prominent CCIs in Normal:

Clinical or Translational Implications

The distinct CCI profiles across breast cancer subtypes highlight opportunities for targeted therapeutic interventions and personalized medicine.

Subtype-Specific Targeting:

Further research focusing on the functional consequences of these specific interactions using *in vitro* and *in vivo* models, and validating them in larger patient cohorts, will be crucial to translate these findings into effective clinical strategies.

14. Condition-Specific Cell-Cell Interaction Patterns Involving Immune Checkpoint and Cell Cycle Pathways in Breast Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes cell-cell interactions (CCIs) involving a predefined set of immune checkpoint and cell cycle pathway genes within epithelial cells, major immune cells, and stromal cells across different breast cancer conditions (ER+, HER2+, TNBC) and normal breast tissue. The dot plot displays the strength and significance of these interactions per sample within each condition, allowing for a comparative assessment of the tumor microenvironment (TME) dynamics. The interaction partners include both diploid (Dip) and aneuploid (Aneup) cell populations, providing insight into the role of transformed cells in mediating these interactions.

Visual Summary

The dot plot visualizes condition-specific CCI patterns, where the color intensity represents the scaled log strength of the interaction, and the dot size reflects the statistical significance (-log10(p-value)).

Biological Interpretation

Condition-Specific Interaction Landscapes

The analysis reveals a dynamic reorganization of cell-cell communication networks in breast cancer, with distinct patterns emerging across different molecular subtypes. The shift from a largely homeostatic interaction profile in normal tissue to one characterized by immune evasion, sustained proliferative signaling, and altered stromal support in tumor conditions highlights the complex interplay within the tumor microenvironment (TME). The frequent involvement of aneuploid cells in these prominent interactions underscores their oncogenic contribution to shaping the TME.

Key Interaction Pathways and Their Biological Roles

  1. Immune Checkpoint Interactions

These interactions are particularly pronounced in HER2+ and TNBC, aligning with their higher immunogenicity and responsiveness to immunotherapy.

CD274_PDCD1 -- Mac | T cell CD8+:

NECTIN2_TIGIT -- Mac | T cell CD8+:

LILRB4_LAG3 -- Mac | T cell CD4+:

CD86_CD28 -- Mac | T cell CD4+:

  1. Growth Factor and Receptor Signaling

These interactions are central to tumor growth, survival, and metastasis, driving cell cycle progression indirectly.

TGFB1_TGFbeta_receptor1 -- Epi (Aneup) | Fib (Dip) / Mac (Aneup) / T cell CD4+:

VEGFA_NRP1 -- Endo | Epi (Aneup):

  1. Extracellular Matrix and Adhesion Interactions

These interactions are fundamental to tissue architecture and are often dysregulated in cancer to facilitate invasion and metastasis.

COL1A1_integrin_a2b1_complex -- Fib (Dip) | Epi (Dip/Aneup) and others:

Clinical or Translational Implications

The observed condition-specific CCI patterns provide actionable insights for breast cancer diagnosis, prognosis, and therapeutic strategies, particularly for the immune-rich HER2+ and TNBC subtypes.

  1. Immunotherapy Biomarkers and Targets: The prominent activation of PD-1/PD-L1, TIGIT, and LAG3 pathways in HER2+ and TNBC samples strongly supports the rationale for immune checkpoint inhibitor therapies in these patients. The identification of specific cell types involved (e.g., macrophages, CD8+ T cells) can guide strategies for modulating the immune microenvironment. These interactions serve as potential predictive biomarkers for response to existing immunotherapies and highlight novel targets for future drug development (e.g., TIGIT, LAG3).
  2. Targeting Proliferative Pathways: The consistent activity of EGFR and related growth factor signaling across tumor subtypes underscores the importance of targeting these pathways. While HER2-targeting therapies are standard for HER2+ breast cancer, the broad involvement of EGFR family ligands suggests that broader EGFR inhibition could be explored for other subtypes, especially when resistance mechanisms develop.
  3. Stromal Targeting and Microenvironment Modulation: The frequent involvement of fibroblasts (both diploid and aneuploid) in CCIs related to growth factors and ECM remodeling (integrins, TGF-beta) highlights the critical role of the tumor stroma in breast cancer progression. Therapeutic strategies aimed at normalizing the TME, such as targeting CAFs or inhibiting TGF-beta signaling, could complement direct anti-tumor approaches.
  4. Aneuploidy as a Driver: The observation that many high-strength, significant interactions in tumor conditions involve aneuploid cells (Epi, Fib, Mac) confirms their pathogenic role. This reinforces the idea that understanding and targeting aneuploid cell-specific vulnerabilities, perhaps through interactions they uniquely engage in, could be a therapeutic avenue.

In summary, this CCI analysis delineates key intercellular communication pathways that are dysregulated in breast cancer, offering valuable leads for developing targeted therapies and improving patient outcomes by leveraging or disrupting these critical interactions within the TME.

15. Epithelial Cell Condition-Specific Surfaceome Markers in Breast Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes surfaceome markers specifically expressed in Epithelial cells across different breast cancer conditions (ER+, HER2+, TNBC) and Normal breast tissue. The aim is to highlight differentially expressed surface proteins that could serve as diagnostic biomarkers or therapeutic targets. The comparison was performed against the Normal condition, with markers selected based on a combination of expression level, fraction of cells expressing, and fold change.

Visual Summary

The dot plot effectively visualizes the expression patterns of numerous surfaceome markers across various samples, grouped by breast cancer subtype (ER+, HER2+, TNBC) and Normal tissue. Each row represents a sample, and each column represents a specific surfaceome gene.

Biological Interpretation

Epithelial cells are the origin of most breast cancers. Characterizing their surfaceome (the complete set of cell-surface proteins) in different cancer subtypes provides a crucial window into cell-cell communication, adhesion, signaling, and potential targets for therapeutics. The differential expression patterns observed reflect the unique molecular landscapes that drive each breast cancer subtype.

Markers in ER+ Epithelial Cells

ER+ breast cancer is characterized by estrogen receptor signaling. Many markers here are likely involved in supporting cell growth, survival, or modulating the tumor microenvironment in an ER-dependent or independent manner.

Established Therapeutic Targets

Less Well-Characterized Markers with Potential

Markers in HER2+ Epithelial Cells

HER2+ breast cancer is defined by the overexpression or amplification of the *ERBB2* gene, encoding the HER2 receptor. Markers here likely interact with HER2 signaling or represent downstream effects.

Established Therapeutic Targets

Less Well-Characterized Markers with Potential

Markers in TNBC Epithelial Cells

Triple-negative breast cancer (TNBC) is characterized by the lack of ER, PR, and HER2 expression, making it a challenging subtype to treat with targeted therapies. Markers in TNBC are often associated with aggressive growth, metastasis, and unique signaling pathways.

Established Therapeutic Targets

Less Well-Characterized Markers with Potential

Clinical or Translational Implications

The identification of condition-specific surfaceome markers in breast cancer epithelial cells has significant clinical and translational implications:

  1. Refined Diagnostics and Prognostics: Markers like ESR1, ERBB2, and EGFR are already part of standard diagnostic panels for breast cancer subtyping. However, the discovery of less common, highly specific surfaceome markers (e.g., SLC39A6, TMEM179B, PLP2) could lead to more precise diagnostic assays, potentially identifying new subgroups or predicting treatment response and patient outcomes more accurately.
  2. Novel Therapeutic Targets: Surface proteins are highly accessible to antibody-based therapies, antibody-drug conjugates (ADCs), and small molecule inhibitors.
  1. Biomarkers for Liquid Biopsies: Circulating tumor cells or extracellular vesicles often carry tumor-specific surface markers. Highly expressed surfaceome markers identified in this analysis could serve as valuable biomarkers for non-invasive monitoring of disease progression, recurrence, or treatment response through liquid biopsies.
  2. Mechanistic Insights: Understanding the roles of these surfaceome markers provides deeper insights into the specific biological processes driving each breast cancer subtype. For example, understanding the involvement of zinc transporters (SLC39A6) or ADAM proteases (ADAM15) can reveal metabolic vulnerabilities or mechanisms of invasion unique to specific subtypes. These insights can guide the development of mechanism-based therapies.

Further validation through functional studies (e.g., gene knockdown/overexpression, _in vitro_ and _in vivo_ models) and analysis in larger patient cohorts would be crucial to translate these findings into clinical practice.

16. Macrophage Condition-Specific Surfaceome Marker Analysis in Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers expressed by Macrophages across different breast cancer subtypes (ER+, HER2+, TNBC) and Normal breast tissue, based on single-cell RNA-seq data. The goal is to uncover potential therapeutic targets and understand the functional roles of macrophages within the tumor microenvironment (TME) specific to each disease context. The dot plot visualizes the mean expression and fraction of cells expressing these markers per sample, grouped by condition. Markers were selected based on their non-zero percentage score and fold change when compared against the reference (Normal) condition, with a strict focus on surfaceome-associated genes.

Visual Summary

The dot plot displays a panel of surfaceome markers in Macrophage cells across various patient samples, categorized into ER+, HER2+, Normal, and TNBC conditions. The size of each dot represents the fraction of cells expressing the marker within that sample, while the color intensity indicates the mean expression level.

Overall, the plot reveals both shared and distinct surface marker profiles for macrophages across different breast cancer subtypes and normal tissue, indicating varied functional states and potential therapeutic vulnerabilities.

Biological Interpretation

Macrophage Markers in ER+ Breast Cancer

In ER+ breast cancer, macrophages often contribute to tumor progression through immune suppression and fostering angiogenesis.

GPNMB (Glycoprotein NMB)

Macrophage Markers in HER2+ Breast Cancer

Macrophages in HER2+ breast cancer can promote resistance to anti-HER2 therapies and contribute to an immunosuppressive environment.

C5AR1 (Complement C5a Receptor 1)

ABCA1 (ATP-Binding Cassette Transporter A1)

Macrophage Markers in Normal Breast Tissue

Macrophages in normal tissue maintain tissue homeostasis, clear debris, and regulate local immune responses.

CD163 (Scavenger Receptor Cysteine-Rich Type 1 Protein M130)

CD47 (Integrin Associated Protein)

Macrophage Markers in TNBC Breast Cancer

TNBC is highly aggressive and often characterized by a significantly immunosuppressive TME, where macrophages play a key role in tumor progression and resistance to therapy.

VSIR (VISTA, V-Domain Ig Suppressor of T Cell Activation)

FCGR2B (Fc Gamma Receptor IIb)

CCR1 (Chemokine (C-C Motif) Receptor 1)

Clinical or Translational Implications

The identification of condition-specific macrophage surface markers provides valuable insights for developing targeted immunotherapies in breast cancer.

17. Fibroblast Condition-Specific Surfaceome Markers in Breast Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes surfaceome markers differentially expressed in Fibroblasts across various breast cancer conditions (ER+, HER2+, TNBC) and Normal breast tissue samples. The goal is to highlight potential cell-type-specific and condition-specific markers, providing insights into Fibroblast heterogeneity and their roles in the tumor microenvironment (TME), as well as their potential as therapeutic targets. The dot plot displays mean expression levels (color intensity) and the fraction of cells expressing the marker (dot size) for individual samples grouped by condition. Markers were selected based on differential expression criteria against the 'Normal' reference condition.

Visual Summary

The dot plot, "Fibroblast condition-specific markers," provides a comprehensive overview of surfaceome marker expression across different breast cancer subtypes and normal tissue.

General Patterns:

Biological Interpretation

Fibroblasts are critical components of the breast tumor microenvironment (TME), often differentiating into Cancer-Associated Fibroblasts (CAFs) that promote tumor growth, invasion, and metastasis. The identified surfaceome markers highlight key signaling pathways and functional roles of fibroblasts in different breast cancer contexts.

Here, we detail several representative markers and their biological implications:

  1. FAP (Fibroblast Activation Protein alpha)
  1. SPP1 (Secreted Phosphoprotein 1; Osteopontin)
  1. CD44 (CD44 Molecule)
  1. EGFR (Epidermal Growth Factor Receptor)
  1. FGFR1 (Fibroblast Growth Factor Receptor 1)
  1. IL1R1 (Interleukin 1 Receptor Type 1)
  1. DDR2 (Discoidin Domain Receptor Tyrosine Kinase 2)
  1. BSG (Basigin; CD147)

Clinical or Translational Implications

The identification of these surfaceome markers on fibroblasts, particularly those differentially expressed across breast cancer subtypes, holds significant clinical and translational potential:

Further research focusing on the functional consequences of these marker expressions in specific breast cancer contexts, combined with *in vivo* validation, will be crucial to translate these findings into effective therapeutic strategies.

---

References:

[1] FAP (Fibroblast Activation Protein alpha) - GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=FAP

[2] FAP breast cancer therapy - PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=FAP+breast+cancer+therapy

[3] SPP1 (Secreted Phosphoprotein 1) - GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=SPP1

[4] SPP1 tumor microenvironment - PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=SPP1+tumor+microenvironment

[5] CD44 breast cancer fibroblasts - PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=CD44+breast+cancer+fibroblasts

[6] FGFR1 breast cancer stroma - PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=FGFR1+breast+cancer+stroma

[7] IL1R1 breast cancer inflammation - PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=IL1R1+breast+cancer+inflammation

[8] DDR2 (Discoidin Domain Receptor Tyrosine Kinase 2) - GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=DDR2

[9] BSG (Basigin, CD147) - GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=BSG

18. T cell CD4+ Surfaceome Marker Expression in Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot illustrating the expression of selected surfaceome markers in T cell CD4+ populations, comparing different breast cancer conditions (ER+, HER2+, Normal, TNBC) against the 'Normal' reference. The plot specifically displays expression profiles across individual patient samples grouped under 'Normal' and 'TNBC' conditions. Each dot's color intensity represents the mean expression level of a marker within the T cell CD4+ cells of a given sample, while the dot's size indicates the fraction of cells expressing that marker within the same group. The analysis parameters prioritize surfaceome-only markers with differential expression against the Normal reference, aiming to identify condition-specific signatures.

Visual Summary

The dot plot displays the expression of 19 surfaceome markers across various patient samples. The samples are broadly categorized into 'Normal' and 'TNBC' conditions.

Biological Interpretation

The observed differential expression of surfaceome markers in T cell CD4+ cells in TNBC compared to normal breast tissue suggests distinct phenotypic adaptations of these immune cells within the tumor microenvironment (TME). These markers are crucial for T cell function, migration, and interaction with other cells, potentially impacting disease progression and therapeutic responses.

Key Differentially Expressed Markers and Their Significance:

  1. CXCR4
  1. CD63
  1. CLEC2D (LLT1)
  1. HLA-E
  1. LY6E

Clinical or Translational Implications

The identification of differentially expressed surfaceome markers on CD4+ T cells within the TNBC microenvironment provides valuable insights into the immunobiology of this aggressive breast cancer subtype.

19. Differential Expression of Cell Cycle Pathway Genes in Breast Epithelial Cells Across Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the expression patterns of a curated set of cell cycle pathway genes within Epithelial cells across different breast cancer conditions (ER+, HER2+, TNBC) and Normal breast tissue. The "expressing cell fraction (sample)" metric, representing the proportion of cells expressing a given gene within each sample, was compared across conditions using box plots, with statistically significant differences highlighted by p-values. The objective was to identify cell cycle genes whose expression is dysregulated in specific breast cancer subtypes, providing insights into their distinct proliferative characteristics.

Visual Summary

The visualization presents 24 box plots, each displaying the expressing cell fraction for a specific cell cycle-related gene across four conditions: ER+, HER2+, Normal, and TNBC. Each box plot includes individual sample data points (black dots) and indicates statistical significance (p-values) for pairwise comparisons between conditions.

Key visual patterns include:

Differences across subtypes:

Complex or varied patterns:

Biological Interpretation

The observed differential expression of cell cycle genes in breast epithelial cells provides critical insights into the proliferative characteristics of different breast cancer subtypes.

Tumor Suppressor and Growth Arrest Genes:

YWHA family (14-3-3 proteins):

In summary, epithelial cells in TNBC exhibit a clear transcriptional signature of enhanced proliferation, marked by the widespread upregulation of DNA replication and cell cycle progression genes. Conversely, several tumor suppressor and growth arrest genes, such as SFN, SMAD3, and GADD45G, show reduced expression in cancerous conditions, suggesting compromised defense mechanisms.

Clinical or Translational Implications

The differential expression of cell cycle pathway genes in breast epithelial cells, particularly the pronounced changes in TNBC, has significant clinical and translational implications:

References:

[1] Minichromosome maintenance (MCM) proteins as diagnostic and prognostic tumor markers. https://pubmed.ncbi.nlm.nih.gov/22426917/

[2] Histone deacetylases (HDACs) and HDAC inhibitors in cancer: from bench to clinic. https://pubmed.ncbi.nlm.nih.gov/20428588/

[3] Targeting cell cycle proteins for cancer therapy: an updated review. https://pubmed.ncbi.nlm.nih.gov/33423548/

[4] Targeting the Cell Cycle for Cancer Therapy. https://pubmed.ncbi.nlm.nih.gov/30526322/

20. Gene Ontology (GSA) Analysis of Epithelial Cells in Breast Cancer Subtypes

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates Gene Ontology (GSA) enrichment in Epithelial cells across various breast cancer conditions (Diploid, ER+, HER2+, TNBC) compared to a normal reference, as well as normal cells compared to all other conditions. The enrichment analysis is based on up-regulated differentially expressed genes (DEGs) in each comparison. The results are visualized as bar plots, displaying the -log(p-val) and -log(q-val) for the most significantly enriched terms, indicating pathways or biological processes that are distinctly active in each condition.

Visual Summary

The bar plots present the top enriched Gene Ontology (GO) terms (pathways/diseases) for epithelial cells, sorted by their statistical significance (-log(p-val) and -log(q-val)).

  1. Consistent Patterns Across Cancer Subtypes (Diploid, ER+, HER2+, TNBC vs. Normal):
  1. Distinct Pattern in Normal_vs_others:

Biological Interpretation

The Gene Ontology (GSA) analysis of epithelial cells reveals significant shifts in biological processes and pathways associated with breast cancer. The consistent upregulation of specific functional categories across different breast cancer subtypes highlights common underlying mechanisms of oncogenesis and tumor progression.

Subtype-Specific Observations:

Clinical or Translational Implications

The identified pathways offer several potential clinical and translational insights for breast cancer:

21. Gene Set Enrichment Analysis (GSEA) Across Breast Cancer Subtypes and Cell Types

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis utilizes Gene Set Enrichment Analysis (GSEA) to identify pathways that are significantly enriched or depleted in various cell types across different breast cancer conditions (ER+, HER2+, TNBC) compared to normal breast tissue. The results are presented as a dot plot, where each dot represents a specific pathway in a particular cell type and condition. The color of the dot indicates the Normalized Enrichment Score (NES), with red signifying enrichment (upregulation) and blue indicating depletion (downregulation). The size of the dot correlates with the statistical significance (-log(p-val)), highlighting the most robust findings. The analysis was performed using gene rankings and compared against a 'Normal' reference condition.

Visual Summary

The dot plot provides a comprehensive overview of activated and suppressed biological pathways across a diverse set of cell types (Epithelial cell, Endothelial cell, Fibroblast, Macrophage, Smooth muscle cell, T cell CD4+, T cell CD8+) within the context of ER+, HER2+, and TNBC breast cancer subtypes, relative to normal tissue.

  1. Widespread Pathway Alterations: Numerous pathways show significant enrichment (red dots) or depletion (blue dots) across multiple cell types and conditions, indicating extensive biological reprogramming in breast cancer.
  2. Cell Type Specificity: Distinct patterns of pathway alterations are observed for different cell types. Epithelial cells, the presumed tumor origin, exhibit a strong and broad spectrum of changes. Stromal cells (Fibroblasts, Smooth muscle cells, Endothelial cells) and immune cells (Macrophages, T cells) also show specific pathway modulations, reflecting their active roles in the tumor microenvironment (TME).
  3. Condition-Dependent Signatures: While some pathways are broadly altered across all breast cancer subtypes, others show specificity. For instance, the "Estrogen signaling pathway" is notably enriched in ER+ epithelial cells.
  4. Key Enriched Pathways: Cancer-associated pathways such as "Pathways in cancer," "Transcriptional misregulation in cancer," "HIF-1 signaling pathway," "ECM-receptor interaction," and various metabolic pathways (e.g., "Glycolysis," "Fatty acid elongation," "Pentose phosphate pathway") are frequently enriched, particularly in epithelial cells and fibroblasts.
  5. Key Depleted Pathways: Pathways related to normal cellular processes or those potentially suppressed by cancer mechanisms also appear, such as "p53 signaling pathway" showing depletion in some epithelial cell conditions, suggesting loss of tumor suppressive function.

Biological Interpretation

Epithelial Cells (Tumor-Origin)

As the primary site of breast cancer, epithelial cells demonstrate profound pathway dysregulation:

Subtype-Specific Signaling:

Stromal Cells (Fibroblasts, Endothelial Cells, Smooth Muscle Cells)

The tumor microenvironment (TME) components exhibit significant changes, indicating active participation in cancer progression:

Immune Cells (Macrophages, T cells CD4+, T cells CD8+)

Immune cells within the TME display context-dependent pathway shifts:

Clinical or Translational Implications

The comprehensive GSEA results offer several insights with potential clinical and translational relevance:

22. Discussion

The single-cell RNA sequencing analysis of breast tissue samples robustly confirms the presence of breast cancer across ER+, HER2+, and TNBC subtypes, providing detailed insights into their heterogeneous cellular and molecular landscapes. UMAP visualizations clearly delineate tumor-origin aneuploid epithelial cells from diploid normal and stromal populations, highlighting genomic instability as a core characteristic of malignancy. This aneuploidy is particularly pervasive in HER2+ and TNBC epithelial cells, while ER+ tumors show more varied ploidy levels, potentially reflecting a broader spectrum of disease progression or genomic complexity within this subtype.

Cell population analysis reveals distinct tumor microenvironment (TME) compositions. TNBC samples consistently exhibit the highest immune cell infiltration, including cytotoxic T cells and macrophages, consistent with its 'immune-hot' phenotype. Conversely, many ER+ samples appear 'immune-cold', although notable heterogeneity exists. This differential immune infiltration is critical, as TNBC's TME, despite higher effector T cells, also shows increased regulatory T cells (Tregs) and M2C macrophages, pointing to active immunosuppression. All cancer subtypes, in contrast to normal tissue, also demonstrate an increase in M1 macrophages, which, in the tumor context, may contribute to chronic inflammation rather than effective anti-tumor immunity.

Cell-cell interaction (CCI) analyses reveal complex, subtype-specific communication networks. Normal tissue interactions emphasize homeostatic ECM and epithelial-stromal balance. In ER+ breast cancer, macrophages extensively interact with aneuploid epithelial cells via axes like APOE-TREM2 and VEGFA-NRP2, promoting angiogenesis and potentially modulating immune responses. HER2+ tumors display an inflamed TME with active chemokine-CCR1 axes and a critical HB-EGF-ERBB2 interaction, suggesting autocrine/paracrine HER2 activation and robust immune cell recruitment. TNBC exhibits the most extensive and immunosuppressive network, characterized by strong SPP1-integrin interactions driving invasion and metastasis, widespread WNT2 signaling, and prominent immune checkpoint interactions such as CD274-PDCD1 (PD-L1/PD-1), NECTIN2-TIGIT, and LILRB4-LAG3. These findings highlight tumor-driven immune evasion and substantial ECM remodeling across all cancer subtypes.

Transcriptomic profiling of surfaceome markers further refines these distinctions. Epithelial cells in ER+ samples show ESR1 and potential targets like SLC39A6. HER2+ epithelial cells are defined by ERBB2 overexpression, alongside markers like CD44. TNBC epithelial cells prominently express EGFR and CD24, with potential targets like PLP2 and MMP1. Macrophages in TNBC upregulate immune checkpoints like VSIR (VISTA), FCGR2B, and CCR1, reinforcing their pro-tumorigenic and immunosuppressive roles. Fibroblasts across all cancer subtypes demonstrate a strong CAF signature with FAP and SPP1, while HER2+ and TNBC fibroblasts additionally express growth factor receptors (EGFR, FGFR1) and inflammatory receptors (IL1R1), indicating active stromal support for aggressive tumor growth. Similarly, CD4+ T cells in TNBC exhibit increased expression of CXCR4, CLEC2D, HLA-E, and LY6E, suggesting altered trafficking, activation, and inhibitory interactions that dampen anti-tumor immunity.

Pathway analyses (GSA and GSEA) universally reveal metabolic reprogramming (e.g., oxidative phosphorylation, glycolysis), elevated protein processing/stress responses, and active cell cycle progression in cancer epithelial cells, particularly in TNBC where DNA replication genes (MCMs, PCNA, MYC) are significantly upregulated. Unexpectedly, pathways associated with neurodegenerative diseases are also enriched, potentially reflecting broad cellular stress responses in cancer. Conversely, tumor suppressor pathways (e.g., p53, SFN, SMAD3) are often depleted or downregulated in cancer cells. These multi-faceted changes underscore the complex adaptive strategies employed by breast cancer cells and their microenvironment to proliferate, evade immunity, and metastasize.

Hypotheses:

  1. Aneuploid epithelial cells universally drive tumor microenvironment reprogramming in breast cancer by secreting factors that recruit and polarize immune and stromal cells, distinct from diploid epithelial cells.
  2. The differential expression of immune checkpoints (e.g., NECTIN2-TIGIT, HLA-E/NKG2A, VSIR) on both tumor-associated immune cells and epithelial cells dictates the responsiveness of breast cancer subtypes to immunotherapy.
  3. Metabolic reprogramming pathways (e.g., oxidative phosphorylation, glycolysis) and protein homeostasis mechanisms are commonly upregulated across all breast cancer epithelial cell subtypes, representing universal therapeutic vulnerabilities independent of traditional receptor status.
  4. The distinct cell-cell interaction networks and surfaceome marker profiles of cancer-associated fibroblasts (CAFs) in HER2+ and TNBC subtypes, involving growth factor receptors (EGFR, FGFR1) and inflammatory pathways (IL1R1), drive unique stromal support mechanisms that could be selectively targeted.
  5. The co-existence of high cytotoxic T cell infiltration and elevated immunosuppressive factors (Tregs, M2C macrophages, specific immune checkpoints) in TNBC creates an "inflamed but suppressed" microenvironment, contributing to its aggressive nature and variable response to single-agent immunotherapies.

Potential therapeutic targets:

  1. ERBB2 (HER2): Amplification/overexpression of ERBB2 is the defining characteristic of HER2+ breast cancer, driving aggressive tumor growth. Its robust expression in HER2+ epithelial cells is confirmed. Evidence: CNV analysis shows strong 17q12 (ERBB2 locus) amplification in HER2+ samples. Epithelial cell surfaceome analysis confirms high ERBB2 expression. Cell-cell interaction (CCI) analysis shows HB-EGF_ERBB2 interaction in HER2+ TME. Validation: Clinical trials and extensive use of anti-HER2 therapies (Trastuzumab, Pertuzumab, Lapatinib, ADCs like T-DM1, T-DXd). Functional validation could involve testing sensitivity of HER2+ tumor cells to these agents in vitro/in vivo, and assessing mechanisms of resistance.
  2. Fibroblast Activation Protein alpha (FAP): FAP is a canonical marker of activated Cancer-Associated Fibroblasts (CAFs), which are critical for extracellular matrix (ECM) remodeling, promoting tumor invasion, angiogenesis, and immune suppression across all breast cancer subtypes. Its restricted expression in normal adult tissues makes it an attractive target. Evidence: Fibroblast surfaceome analysis shows high FAP expression and prevalence across ER+, HER2+, and TNBC conditions, significantly upregulated compared to normal tissue. Validation: Preclinical studies using FAP-targeting antibodies, small molecule inhibitors, or FAP-activated prodrugs in breast cancer models to assess effects on tumor growth, metastasis, ECM remodeling, and immune infiltration. Clinical trials targeting FAP in various cancers are ongoing.
  3. PD-1/PD-L1 Axis (CD274_PDCD1): This immune checkpoint interaction is a major mechanism of immune evasion in cancer, leading to T cell exhaustion and suppression. Blocking this pathway can reinvigorate anti-tumor T cell responses, particularly in immunogenic subtypes like TNBC. Evidence: CCI analysis focusing on immune checkpoints reveals striking activity of CD274_PDCD1 interactions in HER2+ and TNBC, often involving macrophages and CD8+ T cells. T cell subset analysis also shows presence of CD8 Exhausted T cells in tumor samples. Validation: FDA-approved anti-PD-1/PD-L1 antibodies (e.g., Pembrolizumab, Atezolizumab) are used in TNBC. Validation can involve assessing response rates in patients, and in vitro/in vivo studies examining T cell function and tumor regression upon blockade, especially in combination with other agents.
  4. Secreted Phosphoprotein 1 (SPP1) - Integrin Axes: SPP1 (Osteopontin) is a pleiotropic cytokine implicated in inflammation, angiogenesis, metastasis, and immune suppression. Its strong interaction with various integrins on tumor cells and fibroblasts promotes an aggressive phenotype, especially in TNBC. Evidence: CCI analysis highlights widespread and strong SPP1-integrin interactions (e.g., SPP1_integrin_avb1_complex) involving fibroblasts, macrophages, and aneuploid epithelial cells in all cancer subtypes, being particularly prominent in TNBC. Fibroblast surfaceome confirms SPP1 expression in CAFs. Validation: Preclinical studies using neutralizing antibodies against SPP1 or specific integrin receptors (e.g., αvβ1) to inhibit tumor growth, invasion, metastasis, and immune evasion in breast cancer models. Investigate in combination with chemotherapy or immunotherapy.

Follow-up validation ideas:

  1. Flow cytometry or Immunohistochemistry: Validate the protein expression levels and cellular localization of key surfaceome markers (e.g., GPNMB, C5AR1, VSIR, FAP, EGFR, FGFR1, CXCR4, HLA-E, LY6E) on identified cell types (Epithelial, Macrophage, Fibroblast, T cells) in independent breast cancer patient cohorts.
  2. Spatial Transcriptomics or Multiplex Immunofluorescence: Confirm the co-localization and proximity of interacting cell pairs and their expressed ligand-receptor components (e.g., SPP1-integrin between fibroblasts and aneuploid epithelial cells, HB-EGF-ERBB2 on macrophages and epithelial cells) within the tumor tissue architecture.
  3. In vitro Co-culture and Perturbation Assays: Use patient-derived organoids or cell lines in co-culture with relevant stromal/immune cells (e.g., aneuploid epithelial cells with macrophages or fibroblasts) to functionally validate predicted cell-cell interactions. Perturb specific ligand-receptor pairs (e.g., using blocking antibodies, CRISPR knockdown/overexpression) and assess downstream effects on cell proliferation, migration, immune suppression, or TME remodeling.
  4. In vivo Preclinical Models: Test the efficacy of targeting selected therapeutic candidates (e.g., FAP, SPP1, CXCR4, TIGIT, VSIR, C5AR1, EGFR/FGFR1 on fibroblasts) using patient-derived xenograft (PDX) models or genetically engineered mouse models (GEMMs) of breast cancer, assessing tumor growth, metastasis, and immune cell infiltration/function.
  5. Single-cell ATAC-seq or Proteomics: Orthogonally validate the activation states of key pathways (e.g., metabolic reprogramming, cell cycle progression, immune signaling) by examining chromatin accessibility or protein abundance changes in specific cell types, complementing transcriptomic findings.
  6. CRISPR Screening: Conduct in vitro or in vivo functional CRISPR screens targeting genes in enriched metabolic or protein processing pathways in breast cancer epithelial cells to identify critical vulnerabilities.

Limitations:

The current analysis provides a high-resolution transcriptional snapshot; however, direct protein expression and post-translational modifications, which can significantly influence protein function, are not directly measured. Cell-cell interaction predictions derived from transcriptomic data require functional validation to confirm their biological relevance and mechanistic impact. Ploidy estimates, while robust, are inferred from gene expression and should ideally be complemented by direct genomic methods like karyotyping. The dataset, while extensive, is specific to this cohort and may not fully capture the global heterogeneity of breast cancer, limiting generalization. Finally, while correlations are observed, establishing causality for the identified molecular changes and their therapeutic implications requires further experimental investigation through functional studies.

23. Query List

  1. Show and save UMAPs for condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in two columns.
  2. Show major cell type scores on UMAP and save the result.
  3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
  4. Select tumor-origin cells, show a CNV heatmap grouped by sample together with a summary of regions with significantly amplified copy numbers, and save the results.
  5. Show and save UMAPs of CNV patterns colored by major cell type, minor cell type, ploidy results, condition, and sample in two columns.
  6. Show and save a population bar plot of minor cell types.
  7. Show and save a population bar plot of T cell subsets.
  8. Show and save box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
  9. Show and save a population bar plot of macrophage subsets.
  10. Show and save box plots of macrophage subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
  11. Select tumor-origin cells, show their ploidy populations as a bar plot, and save the result.
  12. Show and save cell-cell interaction patterns involving Epithelial cells, fibroblasts, macrophages, T cells, and other relevant cell types. Select at most 80 cell-cell interactions per group.
  13. Find cell-cell interactions involving Epithelial cells, major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms, its potential as a therapeutic target, and relevant therapeutic agents.
  14. Find cell-cell interactions containing immune checkpoint and cell cycle pathway genes and involving Epithelial cells, major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms, its potential as a therapeutic target, and relevant therapeutic agents.
  15. Show marker expressions for Epithelial cells in a dot plot, and save the result. Use only surfaceome markers, with at most 60 markers per condition. For the markers identified under each condition, distinguish between established therapeutic targets and less well-characterized markers with potential as therapeutic targets. For each marker, using the provided dataset context, describe the associated signaling pathways and mechanisms, relevant therapeutic agents, and supporting evidence.
  16. Show marker expressions for Macrophage in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
  17. Show marker expressions for Fibroblast in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
  18. Show marker expressions for T cell CD4+ in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
  19. Among cell cycle pathway genes, select those with statistically significant expression differences between conditions in Epithelial cells, show box plots, and save the result. Set max_n_items_to_plot to 24 and choose ncols based on the total number of panels for an overall width-to-height ratio of approximately 2:3.
  20. Show and save Gene Ontology (GSA) analysis results for Epithelial cells as a bar plot.
  21. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None.
↑ Top